MIRA INFORM REPORT

 

 

Report Date :

08.06.2013

 

IDENTIFICATION DETAILS

 

Name :

GALEMED CORPORATION

 

 

Registered Office :

87, Li-Gong 2nd Rd., Wu-Jia, I-Lan Hsien

 

 

Country :

Taiwan

 

 

Date of Incorporation :

01.10.1986

 

 

Com. Reg. No.:

22320442

 

 

Legal Form :

Joint Stock Company

 

 

Line of Business :

Manufacturing and trading of medical equipment and etc.

 

 

No. of Employees :

About 150 Employees (Taiwan)

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory 

 

 

Payment Behaviour :

No  Complaints

 

 

Litigation :

Clear 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Taiwan

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 


Taiwan ECONOMIC OVERVIEW

 

Taiwan has a dynamic capitalist economy with gradually decreasing government guidance of investment and foreign trade. Exports, led by electronics, machinery, and petrochemicals have provided the primary impetus for economic development. This heavy dependence on exports exposes the economy to fluctuations in world demand. In 2009, Taiwan's GDP contracted 1.8%, due primarily to a 13.1% year-on-year decline in exports. In 2010 GDP grew 10.7%, as exports returned to the level of previous years, and in 2011, grew 4.1%. In 2012, however, growth fell to 1.3%, because of softening global demand. Taiwan's diplomatic isolation, low birth rate, and rapidly aging population are major long-term challenges. Free trade agreements have proliferated in East Asia over the past several years, but except for the landmark Economic Cooperation Framework Agreement (ECFA) signed with China in June 2010, so far Taiwan has been excluded from this greater economic integration in part because of its diplomatic status. Negotiations continue on such follow-on components of ECFA regarding trade in goods and services. The MA administration has said that the ECFA will serve as a stepping stone toward trade pacts with other key trade partners, which Taiwan subsequently launched with Singapore and New Zealand. Taiwan's Total Fertility rate of just over one child per woman is among the lowest in the world, raising the prospect of future labor shortages, falling domestic demand, and declining tax revenues. Taiwan's population is aging quickly, with the number of people over 65 accounting for 11.2% of the island's total population as of 2012. The island runs a large trade surplus largely because of its surplus with China, and its foreign reserves are the world's fifth largest, behind China, Japan, Saudi Arabia, and Russia. In 2006 China overtook the US to become Taiwan's second-largest source of imports after Japan. China is also the island's number one destination for foreign direct investment. Three financial memorandums of understanding, covering banking, securities, and insurance, took effect in mid-January 2010, opening the island to greater investments from the mainland's financial firms and institutional investors, and providing new opportunities for Taiwan financial firms to operate in China. In August 2012, Taiwan Central Bank signed a memorandum of understanding on cross-Strait currency settlement with its Chinese counterpart. The MOU allows for the direct settlement of Chinese RMB and the New Taiwan dollar across the Strait, which could help develop Taiwan into a local RMB hub. Closer economic links with the mainland bring greater opportunities for the Taiwan economy, but also poses new challenges as the island becomes more economically dependent on China while political differences remain unresolved.

 

Source : CIA

 

 


           

Contact Points

 

Company Name:

Galemed Corporation

Supplied Name:

GALEMED CORPORATION

Trading Address:

87, Li-Gong 2nd Rd., Wu-Jia, I-Lan Hsien, Taiwan, R.O.C.

Supplied Address:

87 LI-GONG 2ND RD.WU-JIE I.LAN TAIWAN 268 Taiwan

Telephone Number:

+886-3-990-8618

Fax Number:

+886-3-990-8245

Notes: The exact name and address are as above.

 

 

Credit Summary

 

Credit Opinion:

Business connections are permissible.

 

 

Company Identification Details

 

Registered Name:

Galemed Corporation

Registered Address:

87, Li-Gong 2nd Rd., Wu-Jia, I-Lan Hsien, Taiwan, R.O.C.

Date of Foundation:

1986-10-1

Registration Number:

22320442

Registry:

MOEA Central Office

Registered Capital:

NTD 151,946,870 (USD 5,090,220)

(As of 2013.6, 1 NTD = 0.0335 USD)

Paid-up Capital:

NTD 151,946,870 (USD 5,090,220)

Legal Representatives:

Qingzhao Li

Legal Form:

Joint Stock Company

Principal Activities:

Manufacturing and trading of medical equipment and etc.

Staff:

About 150 Employees (Taiwan)

Listed at Stock Exchange:

No

Date of Last Annual Return:

2013-1-31

History

 

Subject was incorporated on 1986-10-1 with registered number 22320442 as Joint Stock Company in Taiwan.

 

 

Shareholders

 

Name

Subscription Shares

Qingzhao Li

4,722,008         

 

Meihua Huang

 

5,566,184

 

Yiting Li

212,246

Yizhen Li

274,249

 

The information above is that of subject’s major shareholders.

 

 

Subsidiaries & Branches

 

Branch Companies

Name

I-Lan Branch

Registration Number

16569556

Date of Registration

2008-8-10

Status

Revocation

Date of Revocation

2011-2-5

Manager Name

Qingliang Li

Date of Last Annual Return

2011-2-5

 

Related Company

Name

GaleMed Rohanika Respicare Pvt. Ltd.

Address

E-72, Sector-63, Noida  201 301, U.P.,  India

Telephone Number

+91-92-1279-1770

E-mail

devdutt@galemed-rohanika.com

 

Offices

1

Name

Europe Sales Center

Address

43-45 Portman Square, London, W1H 6HN

Telephone Number

+44-2079-69-2893

Fax Number

+44-2079-69-2800

2

Name

Global Sales Headquarter

Address

10F, 109, Section 6, Min-chiuan East Road.Taipei, Taiwan 114

Telephone Number

+ 886-2-8791-9348

3

Name

Greater China Sales Headquarter

Address

39, Section 3,Haijing East Road, Xiamen, Fujian Province, China

Telephone Number

+ 86-592-668-0568

Research & Development Consulting

Name

North America – A Plus Medical Inc.

Address

5431 Avenida Encinas, Suite G, Carlsbad, CA 92008 U.S.A.

Telephone Number

+1-760-930-4025

Fax Number

+1-760-930-0040

 

Factory

Name

Xiamen Facility I & II

Address

39, Section 3,Haijing East Road, Xiamen, Fujian Province, China

Telephone Number

+86-592-688-0588

Fax Number

+86-592-688-0589

 

Personnel Information

 

Core Management

Directors

1

Name

Qingzhao Li

Position

Board Chairman

Date of Appointment

1997-7-3

2

Name

Meihua Huang

Position

Director

3

Name

Yiting Li

Position

Director

4

Name

Yizhen Li

Position

Supervisor

5

Name

Hongyi Lin

Position

Manager

Date of Appointment

2011-6-1

6

Name

Junlin Li

Position

Manager

Date of Appointment

2004-9-14

7

Name

Lingjie Li

Position

Manager

Date of Appointment

2008-11-5

8

Name

Zhongwen Lin

Position

Manager

Date of Appointment

2009-7-27

 


Personnel Structure

Total Employees

About 150 Employees (Taiwan)

 

 

Operation Information

 

Offices & Factories

 

 

Headquarters

Add

87, Li-Gong 2nd Rd., Wu-Jia, I-Lan Hsien, Taiwan, R.O.C.

 

Production Information

l  The subject is a manufacturer of medical equipment and etc.

l   It is introduced that subject has two factories in I-Lan Hsien, Taiwan and Xiamen, Fujian Province, the mainland of China for production.

l  It is introduced that subject has obtained ISO 13485:2003, ISO 9001: 2008 and etc certifications.

 

Purchase Information

l  The registered activities of subject:

Business Code

Details

1

Planning, development, designing, manufacturing, processing, installing and trading of medical equipment.

2

Planning, development, designing, manufacturing, processing, installing, trading and repairing of medical equipment and its related components.

3

Planning, development, designing, manufacturing, processing, installing, trading and repairing of scientific instruments and equipment, laboratory equipment and their related components.

4

Planning, development, designing, manufacturing, processing, installing, trading and repairing of automation machinery and equipment, information product, computer and related components.

5

Agent of marking price for the domestic and overseas manufacturers.

6

The importing and exporting business of the related above. (Except for licensed business).

l  It is introduced that subject purchase components and etc both in domestic and overseas market.

l  It is introduced that subject imports some equipment and technologies from USA and etc.

Sales Information

l  The subject is mainly engaged in sales of medical equipment and etc.

l  It is introduced that subject’s selling territory covers all over the world.

l  It is introduced that subject’s major customers are hospitals, health care centers and etc.

l  It is introduced that subject’s products are applied to medical treatment, emergency treatment and etc.

Major Products

1

Neonatal Ventilation

2

Airway Management

3

Manual Resuscitator

4

Oxygen Mask

5

Aerosol Delivery Interfaces

6

Humidification

7

Interface for CPAP, NIV and PEP

8

Peak Flow Meter & Lung Muscle Trainer

9

Ventilator Circuits

10

Anesthesia Circuit

11

Durable/Reusable Mask

12

Circuit Connectors

13

Valve for Resuscitation

14

Tubing

15

Clamp

16

Circuit Hanger

17

Veterinary

 

Import and export right:

Import right

Yes

Export right

Yes

 

 

Settlements

 

Purchase

Domestic Purchase

Product

Payment Terms

Proportion

Components and etc

COD, CBD and etc

100%

 

Foreign Purchase

Product

Payment Terms

Proportion

Components and etc

CBD and etc

100%

Sales

Domestic Markets

Product

Sales Terms

Proportion

Medical equipment and etc.

COD, CBD and etc

100%

Export

Product

Sales Terms

Proportion

Medical equipment and etc.

CBD and etc

100%

 

 

Financial Information

 

Subject has no obligations to disclose its financial statements to the third party according to the relevant policy in Taiwan and the only source from which we can obtain the information is the subject itself.

 

Subject’s relevant staff Mr. Li declined to disclose its financials citing the grounds of company’s confidentiality; from other source we can not obtain the relevant information, either.

 

 

Bankers

Subject declined to disclose its bank details; from other source we cannot obtain the relevant information, either.

Public Record

 

Mortgage

No chattel mortgage record of subject has been found within the recent 3 months.

 

Lawsuit

Up to date of reporting, no existing or latent litigation of the subject has been found.

 

Interview Details

 

Name

Mr. Li

Department

Sales Department

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.56.74

UK Pound

1

Rs.88.53

Euro

1

Rs.75.20

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.